AGL - Daiichi Sankyo Confo ink deal to develop CNS treatments
2023-03-30 13:17:06 ET
- Daiichi Sankyo ( OTCPK:DSKYF ) and Belgium-based Confo Therapeutics have agreed to collaborate on the discovery of small molecule agonists against an undisclosed target associated with central nervous system diseases.
- Terms call for Confo to receive up to Euro 168M (~$183.2M) based on upfront payment and potential milestones.
- Confo will head the discovery process using its G protein-coupled receptor ( GPCR ) platform to generate a series of small molecule compounds. Daiichi Sankyo ( OTCPK:DSNKY ) has an exclusive option to acquire a worldwide exclusive license for the resulting compounds and advancing them towards further development and commercialization.
For further details see:
Daiichi Sankyo, Confo ink deal to develop CNS treatments